Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
27-30 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
27-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
15 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/belhaven-biopharma-announces-positive-data-from-their-nasdepir-dose-c-1013470
22 Jan 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-01-21/belhaven-biopharma-raises-11m-to-advance-nasdepi-r-the-dry-powder-nasal-breakthrough-for-anaphyla-1
11 Dec 2024
// ACCESSWIRE
24 Oct 2024
// ACCESSWIRE
https://www.accesswire.com/932853/belhaven-biopharma-to-present-promising-phase-1-data-on-needle-free-epinephrine-powder-at-acaai-annual-meeting
22 Oct 2024
// ACCESSWIRE
https://www.accesswire.com/934293/belhaven-biopharmas-nasdepir-named-finalist-for-2024-fierce-innovation-awards-in-drug-delivery-technology
09 Jul 2024
// ACCESSWIRE
Details:
Nasdepi is a dry powder formulation of epinephrine being developed for intranasal administration to treat Type 1 allergic reactions including anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Nasdepi
Study Phase: Phase IIIProduct Type: Hormone
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Belhaven Reports Positive Nasdepi Dose Study in Allergic Rhinitis Patients
Details : Nasdepi is a dry powder formulation of epinephrine being developed for intranasal administration to treat Type 1 allergic reactions including anaphylaxis.
Product Name : Nasdepi
Product Type : Hormone
Upfront Cash : Inapplicable
April 15, 2025
Details:
The financing from the proceeds will support the development of Nasdepi (epinephrine). It is being evaluated for the treatment of Anaphylactic reactions due to severe allergies.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Nasdepi
Study Phase: PreclinicalProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 22, 2025
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $11.0 million
Deal Type : Financing
Belhaven Raises $11M for Nasdepi(R), Nasal Breakthrough for Anaphylaxis
Details : The financing from the proceeds will support the development of Nasdepi (epinephrine). It is being evaluated for the treatment of Anaphylactic reactions due to severe allergies.
Product Name : Nasdepi
Product Type : Hormone
Upfront Cash : Undisclosed
January 22, 2025
Details:
Nasdepi (epinephrine) a small molecule, dry powder nasal formulation is currently being investigated for the treatment of patients with anaphylactic reactions due to severe allergies.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Brand Name: Nasdepi
Study Phase: PreclinicalProduct Type: Hormone
Sponsor: Lovelace Biomedical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 07, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Lovelace Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution in Canine Study
Details : Nasdepi (epinephrine) a small molecule, dry powder nasal formulation is currently being investigated for the treatment of patients with anaphylactic reactions due to severe allergies.
Product Name : Nasdepi
Product Type : Hormone
Upfront Cash : Inapplicable
September 07, 2024
ABOUT THIS PAGE